Sands Capital, an investment management company, released its “Sands Capital Select Growth Fund” Q4 2024 investor letter. A ...

Shares of DexCom Inc. DXCM shed 9.30% to $61.80 Thursday, on what proved to be an all-around grim trading session for the ...

DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost ...

DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic ...

The general mood among these heavyweight investors is divided, with 12% leaning bullish and 50% bearish. Among these notable ...

DexCom receives a warning letter from the FDA citing several issues with its popular G6 & G7 sensor manufacturing. The ...

DexCom Inc. closed 52.01% short of its 52-week high of $141.99, which the company achieved on April 9th.

We recently published a list of 10 Best Diabetes Stocks To Buy According to Billionaires. In this article, we are going to take a look at where DexCom, Inc.

DexCom DXCM recently signed a licensing and data partnership with a privately held healthcare-at-home digital diagnostics company — Nanowear. Per the terms of the agreement, Nanowear will use ...

(Reuters) -Megacap U.S. tech companies including Apple (NASDAQ: AAPL) and retail giants Walmart (NYSE: WMT) and Nike (NYSE: ...